AP2012006262A0 - Monoclonal antibodies to progastrin and their uses. - Google Patents

Monoclonal antibodies to progastrin and their uses.

Info

Publication number: AP2012006262A0
Authority: AP; ARIPO
Prior art keywords: progastrin; monoclonal antibodies; monoclonal; antibodies
Prior art date: 2009-10-16

Application number

AP2012006262A

Other languages

English (en)

Inventor

Dominique Joubert

Laure Boudier

Julie Pannequin

Original Assignee

Biorealites Inst Nat De La Sante Et De Larech Medicale Inserm

Ct Nat De La Rech Scient Snrs

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-10-16

Filing date

2010-10-15

Publication date

2012-06-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43086711&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP2012006262(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2010-10-15 Application filed by Biorealites Inst Nat De La Sante Et De Larech Medicale Inserm, Ct Nat De La Rech Scient Snrs filed Critical Biorealites Inst Nat De La Sante Et De Larech Medicale Inserm

2012-06-30 Publication of AP2012006262A0 publication Critical patent/AP2012006262A0/xx

Links

101800000285 Big gastrin Proteins 0.000 title 1
RZIMNEGTIDYAGZ-HNSJZBNRSA-N pro-gastrin Chemical compound N([C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)NCC(=O)NCC(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)C(=O)[C@@H]1CCC(=O)N1 RZIMNEGTIDYAGZ-HNSJZBNRSA-N 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57419—Specifically defined cancers of colon
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/595—Gastrins; Cholecystokinins [CCK]

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Biomedical Technology (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Biochemistry (AREA)
Cell Biology (AREA)
Microbiology (AREA)
Genetics & Genomics (AREA)
Biotechnology (AREA)
Physics & Mathematics (AREA)
General Physics & Mathematics (AREA)
Biophysics (AREA)
Pathology (AREA)
Hospice & Palliative Care (AREA)
Oncology (AREA)
Analytical Chemistry (AREA)
Food Science & Technology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Endocrinology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Mycology (AREA)
Epidemiology (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

AP2012006262A 2009-10-16 2010-10-15 Monoclonal antibodies to progastrin and their uses. AP2012006262A0 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US25262509P	2009-10-16	2009-10-16
PCT/EP2010/006329 WO2011045080A2 (en)	2009-10-16	2010-10-15	Monoclonal antibodies to progastrin and their uses

Publications (1)

Publication Number	Publication Date
AP2012006262A0 true AP2012006262A0 (en)	2012-06-30

Family

ID=43086711

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AP2012006262A AP2012006262A0 (en)	2009-10-16	2010-10-15	Monoclonal antibodies to progastrin and their uses.

Country Status (42)

Country	Link
US (7)	US9611320B2 (ro)
EP (2)	EP3421493B1 (ro)
JP (3)	JP5985987B2 (ro)
KR (2)	KR101640520B1 (ro)
CN (2)	CN102791735B (ro)
AP (1)	AP2012006262A0 (ro)
AR (1)	AR078659A1 (ro)
AU (1)	AU2010306119A1 (ro)
BR (1)	BR112012008818B1 (ro)
CA (1)	CA2777691C (ro)
CL (1)	CL2012000914A1 (ro)
CR (1)	CR20120184A (ro)
CU (1)	CU24196B1 (ro)
CY (1)	CY1120913T1 (ro)
DK (1)	DK2488551T3 (ro)
EA (2)	EA029271B1 (ro)
EC (1)	ECSP12011796A (ro)
ES (2)	ES2973217T3 (ro)
GE (1)	GEP201706604B (ro)
GT (1)	GT201200114A (ro)
HN (1)	HN2012000708A (ro)
HR (1)	HRP20181645T1 (ro)
IL (2)	IL219019B (ro)
IN (1)	IN2012DN03348A (ro)
LT (1)	LT2488551T (ro)
MA (1)	MA33747B1 (ro)
MX (1)	MX351635B (ro)
NI (1)	NI201200054A (ro)
NZ (2)	NZ599971A (ro)
PE (1)	PE20121649A1 (ro)
PH (1)	PH12012500711B1 (ro)
PL (2)	PL2488551T3 (ro)
PT (1)	PT2488551T (ro)
RS (1)	RS57966B1 (ro)
SG (1)	SG10201704933PA (ro)
SI (1)	SI2488551T1 (ro)
SM (1)	SMT201800628T1 (ro)
TN (1)	TN2012000159A1 (ro)
TW (1)	TWI537002B (ro)
UA (1)	UA106771C2 (ro)
WO (1)	WO2011045080A2 (ro)
ZA (1)	ZA201202642B (ro)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7854932B2 (en)	2006-12-19	2010-12-21	The Board Of Regents Of The University Of Texas System	Immunogenic compositions comprising progastrin and uses thereof
US8136651B2 (en) *	2007-12-14	2012-03-20	The Procter & Gamble Company	Method and apparatus for orienting articles
BR112012008818B1 (pt) *	2009-10-16	2021-10-19	Institut National de la Santé et de la Recherche Medicale (INSERM)	Anticorpo monoclonal anti-hpg, composição e uso dos mesmos
US9487582B2 (en) *	2010-01-08	2016-11-08	Institut National De La Sante Et De La Recherche Medicale (Inserm)	Methods for treating pancreatic cancer
US8900817B2 (en)	2010-01-08	2014-12-02	Les Laboratories Servier	Progastrin and liver pathologies
BR112012024036B1 (pt) *	2010-03-24	2020-03-03	Les Laboratoires Servier	Profilaxia de câncer colorretal e gastrointestinal
EA201790882A1 (ru) *	2010-07-26	2017-08-31	Ле Лаборатуар Сервье	Способы и композиции для терапии рака печени
US8785603B2 (en)	2011-05-20	2014-07-22	Siemens Healthcare Diagnostics Inc.	Antibodies to 25-hydroxyvitamin D2 and D3 and uses thereof
US9410955B2 (en)	2011-06-01	2016-08-09	Inserm (Institut National De La Sante Et De La Recherche Medicale)	Method for predicting the risk of developing a colonic neoplasia
EP3708189B1 (en) *	2013-07-05	2023-11-29	University of Washington through its Center for Commercialization	Soluble mic neutralizing monoclonal antibody for treating cancer
RU2699717C2 (ru) *	2014-04-18	2019-09-09	Дзе Ресёч Фаундэйшен Фор Дзе Штат Юниверсити Ов Нью-Йорк	Гуманизированные антитела к антигену Томсена-Фриденрайха
US10023651B2 (en)	2014-04-18	2018-07-17	The Research Foundation For The State University Of New York	Humanized anti-TF-antigen antibodies
WO2016066671A1 (en)	2014-10-29	2016-05-06	INSERM (Institut National de la Santé et de la Recherche Médicale)	Method for treating resistant cancers using progastrin inhibitors
WO2017048629A1 (en) *	2015-09-15	2017-03-23	The Scripps Research Institute	Antibodies for generating anti-inflammatory macrophage and related uses
CN114705858A (zh) *	2015-12-31	2022-07-05	Syncerus有限责任公司	用于评估癌症发生的风险的组合物和方法
ES3011729T3 (en) *	2015-12-31	2025-04-08	Ecs Progastrin Sa	Compositions and methods for detecting and treating gastric cancer
CA3009751A1 (en) *	2015-12-31	2017-07-06	Progastrine Et Cancers S.A R.L.	Compositions and methods for detecting and treating ovarian cancer
EA201992317A1 (ru) *	2017-03-30	2020-03-05	Эсс-Прогастрин Са	Композиции и способы для диагностики рака легких
ES2904939T3 (es) *	2017-03-30	2022-04-06	Progastrine Et Cancers S A R L	Composiciones y métodos para detectar y tratar el cáncer de próstata utilizando una molécula de unión a progastrina
ES2920283T3 (es) *	2017-12-05	2022-08-02	Progastrine Et Cancers S A R L	Terapia de combinación entre un anticuerpo antiprogastrina y la inmunoterapia para tratar el cáncer
AU2018381046A1 (en)	2017-12-08	2020-07-16	Ecs-Biotracker Sàrl	Radiolabeled progastrin in cancer diagnosis
WO2019145537A1 (en)	2018-01-26	2019-08-01	Ecs-Progastrin Sa	Combination of progastrin detection with other cancer biomarkers in cancer diagnosis
SG11202008271QA (en) *	2018-02-27	2020-09-29	Ecs Progastrin Sa	Progastrin as a biomarker for immunotherapy
TWI793238B (zh) *	2018-12-27	2023-02-21	偉喬生醫股份有限公司	體外檢測生物樣品之胃源性蛋白的方法及套組
US20220372125A1 (en) *	2019-10-02	2022-11-24	Aslan Pharmaceuticals Pte. Ltd.	Antigen Specific Binding Domains and Antibody Molecules
CN112062846A (zh) *	2020-04-27	2020-12-11	杭州博茵生物技术有限公司	一种g-17单克隆抗体及其应用
CN115785273B (zh) *	2021-09-10	2023-10-31	东莞市朋志生物科技有限公司	一种抗胃蛋白酶原i的抗体及其应用
CN115724949A (zh) *	2022-12-12	2023-03-03	郑州伊美诺生物技术有限公司	一种鼠源lgG单克隆抗体及其制备方法、应用
CN116143920A (zh) *	2022-12-30	2023-05-23	南京岚煜生物科技有限公司	胃泌素17的单克隆抗体及其细胞株的制备方法和应用
US20250059271A1 (en) *	2023-08-16	2025-02-20	Barrelman Biosciences Llc	Monoclonal antibodies against veterinary progastrin-like molecules and their uses
CN117567611B (zh) *	2023-11-22	2024-05-14	艾维可生物科技有限公司	抗成熟型胃泌素17的单克隆抗体及其应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5179017A (en)	1980-02-25	1993-01-12	The Trustees Of Columbia University In The City Of New York	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en)	1980-02-25	1983-08-16	The Trustees Of Columbia University	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en)	1980-02-25	1987-01-06	The Trustees Of Columbia University In The City Of New York	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en)	1982-11-18	1985-04-09	Chiron Corporation	Adenovirus promoter system
GB8308235D0 (en)	1983-03-25	1983-05-05	Celltech Ltd	Polypeptides
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US5807715A (en)	1984-08-27	1998-09-15	The Board Of Trustees Of The Leland Stanford Junior University	Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5168062A (en)	1985-01-30	1992-12-01	University Of Iowa Research Foundation	Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4737456A (en)	1985-05-09	1988-04-12	Syntex (U.S.A.) Inc.	Reducing interference in ligand-receptor binding assays
US4968615A (en)	1985-12-18	1990-11-06	Ciba-Geigy Corporation	Deoxyribonucleic acid segment from a virus
GB8607679D0 (en)	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
GB8720833D0 (en)	1987-09-04	1987-10-14	Celltech Ltd	Recombinant dna product
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
GB8928874D0 (en)	1989-12-21	1990-02-28	Celltech Ltd	Humanised antibodies
US6150584A (en)	1990-01-12	2000-11-21	Abgenix, Inc.	Human antibodies derived from immunized xenomice
AU633698B2 (en)	1990-01-12	1993-02-04	Amgen Fremont Inc.	Generation of xenogeneic antibodies
US5545806A (en)	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
EP0519596B1 (en)	1991-05-17	2005-02-23	Merck & Co. Inc.	A method for reducing the immunogenicity of antibody variable domains
IE922437A1 (en)	1991-07-25	1993-01-27	Idec Pharma Corp	Recombinant antibodies for human therapy
ES2136092T3 (es)	1991-09-23	1999-11-16	Medical Res Council	Procedimientos para la produccion de anticuerpos humanizados.
EP0746609A4 (en)	1991-12-17	1997-12-17	Genpharm Int	NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES
US5639641A (en)	1992-09-09	1997-06-17	Immunogen Inc.	Resurfacing of rodent antibodies
GB9625640D0 (en)	1996-12-10	1997-01-29	Celltech Therapeutics Ltd	Biological products
DK1794586T3 (da) *	2004-09-22	2013-05-13	Cancer Advances Inc	Monoklonale antistoffer til progastrin
CA2652768A1 (en)	2006-05-22	2007-11-29	Inserm (Institut National De La Sante Et De La Recherche Medicale)	Inhibitors of progastrin-induced repression of icat for treating and/or preventing colorectal cancer, adenomatous polyposis or metastasis displaying progastrin-secreting cells andcells in which the beta-catenin/tcf-4-mediated transcriptional pathway is constitutively active
US7854932B2 (en)	2006-12-19	2010-12-21	The Board Of Regents Of The University Of Texas System	Immunogenic compositions comprising progastrin and uses thereof
US20110318380A1 (en) *	2008-10-01	2011-12-29	Dako Denmark A/S	MHC Multimers in Cancer Vaccines and Immune Monitoring
BR112012008818B1 (pt) *	2009-10-16	2021-10-19	Institut National de la Santé et de la Recherche Medicale (INSERM)	Anticorpo monoclonal anti-hpg, composição e uso dos mesmos
BR112012024036B1 (pt) *	2010-03-24	2020-03-03	Les Laboratoires Servier	Profilaxia de câncer colorretal e gastrointestinal

2010
- 2010-10-15 BR BR112012008818-1A patent/BR112012008818B1/pt active IP Right Grant
- 2010-10-15 GE GEAP201012707A patent/GEP201706604B/en unknown
- 2010-10-15 ES ES18185172T patent/ES2973217T3/es active Active
- 2010-10-15 SI SI201031788T patent/SI2488551T1/sl unknown
- 2010-10-15 EA EA201200597A patent/EA029271B1/ru not_active IP Right Cessation
- 2010-10-15 SG SG10201704933PA patent/SG10201704933PA/en unknown
- 2010-10-15 PE PE2012000434A patent/PE20121649A1/es active IP Right Grant
- 2010-10-15 KR KR1020157017085A patent/KR101640520B1/ko active Active
- 2010-10-15 IN IN3348DEN2012 patent/IN2012DN03348A/en unknown
- 2010-10-15 NZ NZ599971A patent/NZ599971A/en unknown
- 2010-10-15 SM SM20180628T patent/SMT201800628T1/it unknown
- 2010-10-15 DK DK10768878.0T patent/DK2488551T3/en active
- 2010-10-15 UA UAA201205759A patent/UA106771C2/uk unknown
- 2010-10-15 PL PL10768878T patent/PL2488551T3/pl unknown
- 2010-10-15 PT PT10768878T patent/PT2488551T/pt unknown
- 2010-10-15 KR KR1020127012677A patent/KR20120091221A/ko not_active Ceased
- 2010-10-15 JP JP2012533531A patent/JP5985987B2/ja active Active
- 2010-10-15 US US12/906,041 patent/US9611320B2/en active Active
- 2010-10-15 AR ARP100103784A patent/AR078659A1/es active IP Right Grant
- 2010-10-15 AU AU2010306119A patent/AU2010306119A1/en not_active Abandoned
- 2010-10-15 EP EP18185172.6A patent/EP3421493B1/en active Active
- 2010-10-15 HR HRP20181645TT patent/HRP20181645T1/hr unknown
- 2010-10-15 CN CN201080057237.3A patent/CN102791735B/zh active Active
- 2010-10-15 WO PCT/EP2010/006329 patent/WO2011045080A2/en active Application Filing
- 2010-10-15 CA CA2777691A patent/CA2777691C/en active Active
- 2010-10-15 MX MX2012004400A patent/MX351635B/es active IP Right Grant
- 2010-10-15 TW TW099135321A patent/TWI537002B/zh active
- 2010-10-15 RS RS20181241A patent/RS57966B1/sr unknown
- 2010-10-15 PH PH1/2012/500711A patent/PH12012500711B1/en unknown
- 2010-10-15 EP EP10768878.0A patent/EP2488551B1/en active Active
- 2010-10-15 AP AP2012006262A patent/AP2012006262A0/xx unknown
- 2010-10-15 LT LTEP10768878.0T patent/LT2488551T/lt unknown
- 2010-10-15 CN CN201410752851.1A patent/CN104628857A/zh active Pending
- 2010-10-15 ES ES10768878.0T patent/ES2690943T3/es active Active
- 2010-10-15 PL PL18185172.6T patent/PL3421493T3/pl unknown
- 2010-10-15 EA EA201791876A patent/EA201791876A1/ru unknown
- 2010-10-15 NZ NZ701709A patent/NZ701709A/en unknown
2012
- 2012-04-03 IL IL219019A patent/IL219019B/en active IP Right Grant
- 2012-04-04 TN TNP2012000159A patent/TN2012000159A1/en unknown
- 2012-04-11 CL CL2012000914A patent/CL2012000914A1/es unknown
- 2012-04-12 ZA ZA2012/02642A patent/ZA201202642B/en unknown
- 2012-04-13 NI NI201200054A patent/NI201200054A/es unknown
- 2012-04-13 EC ECSP12011796 patent/ECSP12011796A/es unknown
- 2012-04-13 HN HN2012000708A patent/HN2012000708A/es unknown
- 2012-04-13 CR CR20120184A patent/CR20120184A/es unknown
- 2012-04-16 GT GT201200114A patent/GT201200114A/es unknown
- 2012-04-16 CU CUP2012000060A patent/CU24196B1/es active IP Right Grant
- 2012-05-11 MA MA34864A patent/MA33747B1/fr unknown
2015
- 2015-03-04 JP JP2015042849A patent/JP6272793B2/ja active Active
2017
- 2017-03-06 US US15/451,275 patent/US10377821B2/en active Active
- 2017-03-06 US US15/451,268 patent/US10385125B2/en active Active
- 2017-03-06 US US15/451,253 patent/US10385124B2/en active Active
- 2017-03-06 US US15/451,280 patent/US10385126B2/en active Active
- 2017-06-21 JP JP2017121372A patent/JP2017212992A/ja active Pending
- 2017-08-15 IL IL254004A patent/IL254004B2/en unknown
2018
- 2018-10-22 CY CY181101081T patent/CY1120913T1/el unknown
2019
- 2019-06-28 US US16/456,328 patent/US11299542B2/en active Active
2022
- 2022-03-07 US US17/687,909 patent/US20220195035A1/en active Pending

Also Published As

Publication number	Publication date
IL254004A0 (en)	2017-10-31
WO2011045080A3 (en)	2011-07-07
ES2690943T3 (es)	2018-11-23
US10385125B2 (en)	2019-08-20
UA106771C2 (uk)	2014-10-10
US10385126B2 (en)	2019-08-20
MA33747B1 (fr)	2012-11-01
EA201200597A1 (ru)	2012-12-28
SMT201800628T1 (it)	2019-01-11
TWI537002B (zh)	2016-06-11
CN102791735A (zh)	2012-11-21
AR078659A1 (es)	2011-11-23
CN102791735B (zh)	2016-05-18
JP2015145380A (ja)	2015-08-13
NZ701709A (en)	2016-06-24
US20180022802A1 (en)	2018-01-25
JP2017212992A (ja)	2017-12-07
DK2488551T3 (en)	2018-10-08
EP2488551B1 (en)	2018-07-25
EP2488551A2 (en)	2012-08-22
PL3421493T3 (pl)	2024-04-29
RS57966B1 (sr)	2019-01-31
KR101640520B1 (ko)	2016-07-19
CR20120184A (es)	2012-08-20
WO2011045080A2 (en)	2011-04-21
ES2973217T3 (es)	2024-06-19
SI2488551T1 (sl)	2019-01-31
EA201791876A1 (ru)	2018-01-31
MX351635B (es)	2017-10-23
NI201200054A (es)	2012-08-20
MX2012004400A (es)	2012-06-27
ECSP12011796A (es)	2012-06-29
CN104628857A (zh)	2015-05-20
US20170174761A1 (en)	2017-06-22
KR20150082672A (ko)	2015-07-15
IL219019B (en)	2019-05-30
US10385124B2 (en)	2019-08-20
CA2777691C (en)	2018-02-27
CU24196B1 (es)	2016-09-30
NZ599971A (en)	2014-12-24
BR112012008818B1 (pt)	2021-10-19
PT2488551T (pt)	2018-10-31
US11299542B2 (en)	2022-04-12
CY1120913T1 (el)	2019-12-11
IL219019A0 (en)	2012-06-28
CL2012000914A1 (es)	2012-09-14
CA2777691A1 (en)	2011-04-21
PH12012500711B1 (en)	2019-04-24
PL2488551T3 (pl)	2019-01-31
HRP20181645T1 (hr)	2018-12-14
EP3421493A1 (en)	2019-01-02
JP2013507138A (ja)	2013-03-04
PE20121649A1 (es)	2012-12-08
HK1178183A1 (zh)	2013-09-06
JP5985987B2 (ja)	2016-09-06
US20200002413A1 (en)	2020-01-02
IL254004B2 (en)	2023-06-01
HN2012000708A (es)	2015-06-22
EP3421493C0 (en)	2024-01-17
ZA201202642B (en)	2013-06-26
GEP201706604B (en)	2017-01-25
LT2488551T (lt)	2018-10-25
TN2012000159A1 (en)	2013-12-12
US20110117086A1 (en)	2011-05-19
EP3421493B1 (en)	2024-01-17
US10377821B2 (en)	2019-08-13
EA029271B1 (ru)	2018-03-30
KR20120091221A (ko)	2012-08-17
SG10201704933PA (en)	2017-07-28
US20170306012A1 (en)	2017-10-26
US9611320B2 (en)	2017-04-04
TW201119675A (en)	2011-06-16
GT201200114A (es)	2014-08-11
AU2010306119A1 (en)	2012-05-03
IN2012DN03348A (ro)	2015-10-23
CU20120060A7 (es)	2013-04-19
PH12012500711A1 (en)	2012-11-12
US20170306011A1 (en)	2017-10-26
BR112012008818A2 (pt)	2018-05-22
JP6272793B2 (ja)	2018-01-31
US20220195035A1 (en)	2022-06-23

Publication	Publication Date	Title
IL254004A0 (en)	2017-10-31	Monoclonal antibodies to progesterone and their use
AP2011005984A0 (en)	2011-12-31	Antibodies specific to cadherin-17.
IL214996A0 (en)	2011-11-30	Anti-bcma antibodies
GB0920127D0 (en)	2009-12-30	Antibodies
GB0909906D0 (en)	2009-07-22	Antibodies
ZA201202227B (en)	2014-11-26	Monoclonal antibodies
ZA201104545B (en)	2012-03-28	Anti-siglec-15 antibody
PL2510011T3 (pl)	2015-02-27	Przeciwciała monoklonalne, które wiążą B7H6 i ich zastosowania
IL217919A0 (en)	2012-03-29	Humanized anti-cdcp1 antibodies
EP2427496A4 (en)	2013-05-15	ANTI-VEGF-D ANTIBODIES
GB0920324D0 (en)	2010-01-06	Antibodies
EP2499256A4 (en)	2013-09-11	ANTI-C-MPL ANTIBODIES
IL214755A0 (en)	2011-11-30	Anti-rhesus d monoclonal antibody
GB2473934B (en)	2012-11-28	Anti-VEEV antibody
GB0908945D0 (en)	2009-07-01	Antibodies
GB0911712D0 (en)	2009-08-19	Antibody